News
-
Imatinib’s Impact on Reducing Painful Episodes in Sickle Cell Disease
Currently, hydroxyurea (HU) is the only FDA-approved drug highly recommended for treating sickle cell anemia. However, its efficiency varies among patients with sickle cell disease for unknown reasons. Given the…
Read More » -
WEBINAR | Official Launch of TIF’s Nutrition Guidelines in Thalassaemia and PKD
This essential guide has been eagerly awaited by healthcare professionals and patients alike, and we are pleased to invite you to participate in the event. Date: October 13th, 2023 Time:…
Read More » -
BLOOD TRAΝSFUSION THERAPY | FDA Approves Hemanext ONE®
This revolutionary technology sets a new standard in RBC processing and storage by limiting oxygen in the storage environment, thereby providing a higher quality blood product for patients requiring transfusions.…
Read More » -
WEBINAR | Haemoglobin Disorders and EU Health Policies, 21 September 2023
Designed for patients and their families, these webinars aim to foster national advocacy for the improvement of service delivery. The series will encompass all EU legislative files directly or indirectly…
Read More » -
CLINICAL NEWS | FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS
The approval was based on interim results from the pivotal phase 3 COMMANDS trial (ClinicalTrials.gov Identifier: NCT03682536) that evaluated the efficacy and safety of luspatercept in 356 patients with anemia due to international…
Read More » -
TIF European Health Policy Webinar Series | 21 September 2023
Designed for patients and their families, these webinars aim to foster national advocacy for the improvement of service delivery. The series will encompass all EU legislative files directly or indirectly…
Read More » -
PUBLICATIONS | Nutrition Guidelines in Thalassemia & PKD
Nutrition holds a significant position in the lives of individuals afflicted with thalassaemia and other hereditary anaemias. As part of its enduring commitment to generating guidelines and educational materials for…
Read More » -
IN THE SPOTLIGHT | Explore Our Latest Work in the TIF Newsletter, August Edition
The remarkable collaborations and activities carried out in the past two months have been truly invigorating, and we eagerly anticipate the initiation of upcoming noteworthy endeavours. In this issue, read…
Read More » -
DRUGS | EU Pulls Authorization of Adakveo for Sickle Cell Disease
The decision comes after the Committee on Medicinal Products for Human Use (CHMP) recommended in May 2023 to pull the approval following a review of additional Phase III data. The EC’s decision…
Read More » -
COLD AGGLUTININ DISEASE | Enjaymo Improved Life Quality in Patients for 2.5 Years
“Enjaymo provides sustained and durable treatment benefits in chronic CAD, including a continued meaningful impact on patient quality of life in the long term,” the researchers wrote. However, these benefits…
Read More »